Scientific Advisory Board

The scientific advisors and founders of Alnylam are among the world’s leaders in RNAi and in broad aspects of medical research.

Phillip Sharp, Ph.D.

Institute Professor, The Koch Institute for Integrative Cancer Research, MIT; Former Director, McGovern Institute for Brain Research; Nobel Laureate; founder of Biogen, Inc. (now Biogen Idec, Inc.) and Alnylam; National Academy of Sciences.

Dennis Ausiello, M.D.

Director of the Center for Assessment Technology and Continuous Health (CATCH), Jackson Distinguished Professor of Clinical Medicine at Harvard Medical School and Physician-in-Chief Emeritus at Massachusetts General Hospital.  Director of Pfizer Inc.

David Bartel, Ph.D.

Member of the Whitehead Institute and Professor of Biology at MIT, Investigator of the Howard Hughes Medical Institute, noted RNA and RNAi expert, and a founder of Alnylam.

Nancy J. Brown, M.D.

Professor of Medicine and Pharmacology, Hugh J. Morgan Chair of the Department of Medicine at Vanderbilt University School of Medicine, among first team of scientists to report an increased risk of ACE inhibitor-associated angioedema among African-Americans, American Society for Clinical Investigation and the Association of American Physicians member, specialist in vascular biology and hypertension.

Robert Langer, Ph.D.

Germeshausen Professor at MIT and the only active member of all three U.S. National Academies – the National Academy of Sciences, the Institute of Medicine, and the National Academy of Engineering.

Judy Lieberman, M.D., Ph.D.

Senior Investigator at the Immune Disease Institute, and Professor of Pediatrics, at Harvard Medical School, and the Director of the Division of AIDS at Harvard Medical School.

Muthiah (Mano) Manoharan, Ph.D.

Senior Vice President, Innovation Chemistry & Alnylam Distinguished Scientist, world-leading nucleic acid and bioconjugate chemist, author on more than 200 publications and over 300 abstracts, as well as the inventor on over 180 issued U.S. patents.

Rachel Meyers, Ph.D.

Former head of Research at Alnylam Pharmaceuticals and member of the Scientific Advisory Board at Editas Medicine. During her 13 years with Alnylam, Dr. Meyers played a key role in the advancement of both the RNAi platform and Alnylam’s RNAi therapeutic programs, from early discovery through clinical development. Dr. Meyers has worked closely with Alnylam’s business development and IP groups, playing an integral part in establishing important collaborations, and functioned as scientific lead in collaborations with Novartis, Takeda, Isis, Roche and Genzyme.

Daniel J. Rader, M.D.

Professor of Medicine and chief, Division of Translational Medicine and Human Genetics, at the Perelman School of Medicine at the University of Pennsylvania.

Paul Schimmel, Ph.D.

Hahn Professor of Molecular Biology and Chemistry at Scripps Research Institute, National Academy of Sciences, American Academy of Arts and Sciences, and Institute of Medicine member, cofounder of Cubist, Alkermes and Repligen, and a founder and member of the Board of Directors of Alnylam.

Markus Stoffel, M.D., Ph.D.

Professor for Metabolic Diseases at the Institute of Molecular Systems Biology, Swiss Federal Institute of Technology (ETH) in Zurich.

Thomas Tuschl, Ph.D.

Professor at Rockefeller University, Investigator of the Howard Hughes Medical Institute, noted RNA and RNAi expert, and a founder of Alnylam.

Phillip D. Zamore, Ph.D.

Gretchen Stone Cook Professor of Biomedical Sciences at the University of Massachusetts Medical School, Investigator of the Howard Hughes Medical Institute, noted RNA and RNAi expert, and a founder of Alnylam.